newsfilter
← Latest News
PR Newswire·

MINJUVI® (tafasitamab) for Relapsed or Refractory Follicular Lymphoma Approved in Australia

Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce that Minjuvi® (tafasitamab), in combination with rituximab ...